total sample size of 20, which evidence). 1 study confirmed long term demonstrated that more patients improvement over 24 and 48 weeks. IVIg had similar responded to immunoadsorption than efficacy to Plasma Exchange, oral prednisolone and IVIg, although the baseline disease IV methyl prednisolone in the short term. duration was higher in the IVIg group. Differences were not significant. CIDP is an acquired sensorimotor CIDP is an acquired sensorimotor polyneuropathy Addition: developing over at least 2 months to qualify – and polyneuropathy characterised by a characterised by a progressive or relapsing/ the progression of disease required for the diagnosis progressive or relapsing/ remitting remitting course developing over at least 2 months Criteria course with evidence of demyelination with evidence of demyelination on electrophysiological or pathological electrophysiological or pathological studies and studies and response to response to immunomodulating therapies. immunomodulating therapies. There is no specific diagnostic test, but characteristic There is no specific diagnostic test, but clinical and laboratory findings help distinguish this characteristic clinical and laboratory disorder from other immune mediated neuropathic findings help distinguish this disorder syndromes. Serum protein electrophoresis with from other immune mediated immunofixation may be indicated to search for neuropathic syndromes. Serum protein monoclonal gammopathy and associated conditions. electrophoresis with immunofixation may be indicated to search for monoclonal gammopathy and associated conditions. Diagnosis Yes By specialty General Yes By which specialty Neurologist The system validates the requirement for diagnosis. physician is Diagnosis is recommended to be limited to required or neurologists, if Ig is to be used. Neurologist In order to support ongoing local rural patient care in some jurisdictions, once stable, patient referral to general physicians for review & ongoing management
total sample size of 20, which demonstrated that more patients responded to immunoadsorption than IVIg, although the baseline disease duration was higher in the IVIg group. Differences were not significant. evidence). 1 study confirmed long term improvement over 24 and 48 weeks. IVIg had similar efficacy to Plasma Exchange, oral prednisolone and IV methyl prednisolone in the short term. and Criteria CIDP is an acquired sensorimotor polyneuropathy characterised by a progressive or relapsing/ remitting course with evidence of demyelination electrophysiological or pathological studies and response to immunomodulating therapies. There is no specific diagnostic test, but characteristic clinical and laboratory findings help distinguish this disorder from other immune mediated neuropathic syndromes. Serum protein electrophoresis with immunofixation may be indicated to search for monoclonal gammopathy and associated conditions. CIDP is an acquired sensorimotor polyneuropathy characterised by a progressive or relapsing/ remitting course developing over at least 2 months with evidence of demyelination on electrophysiological or pathological studies and response to immunomodulating therapies. There is no specific diagnostic test, but characteristic clinical and laboratory findings help distinguish this disorder from other immune mediated neuropathic syndromes. Serum protein electrophoresis with immunofixation may be indicated to search for monoclonal gammopathy and associated conditions. Addition: developing over at least 2 months – to qualify the progression of disease required for the diagnosis Diagnosis is required Yes By specialty General physician or Neurologist Yes By which specialty Neurologist The system validates the requirement for diagnosis. Diagnosis is recommended to be limited to neurologists, if Ig is to be used. In order to support ongoing local rural patient care in some jurisdictions, once stable, patient referral to general physicians for review & ongoing management